Characterization of Ph-negative abnormal clones emerging during imatinib therapy

Cancer

Volumn 109, Issue 12, 2007, Pages 2466-2472

  Abruzzese, Elisabetta ^a,d   Gozzetti, Alessandro ^b   Galimberti, Sara ^c   Trawinska, Malgorzata Monika ^a   Caravita, Tommaso ^a   Siniscalchi, Agostina ^a   Cervetti, Giulia ^c   Mauriello, Alessandro ^a   Coletta, Angela Maria ^a   De Fabritiis, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

Author keywords

Chromosomal abnormalities; Chronic myeloid leukemia; Imatinib; Ph negative clones

Indexed keywords

CYTARABINE; DASATINIB; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; INTERFERON; MERCAPTOPURINE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CELL CULTURE; CANCER GROWTH; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; MYELODYSPLASIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL SEPARATION; CELLS, CULTURED; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; MALE; METAPHASE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 34250180917     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22699     Document Type: Article

References (32)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myeloid leukaemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
2. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306:239-242.
3. Deininger MWN, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90:3691-3698.
4. Marley SB, Deininger MWN, Davidson RJ, Goldman JM, Gordon MY. The tyrosine kinase inhibitor STI571, like interpheron-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol. 2000;28:551-557.
5. Hehlmann R. Trial of STI571 before proceeding to allografting for CML? Leukemia. 2000;14:1560-1562.
6. Talpaz DM. STI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002;119:15-24.
7. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukaemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003;17:481-487.
8. Andersen MK. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia. 2002;16:1390-1395.
9. Bumm T, Muller C, Al-Ali HK, Krohn K, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood. 2003;101:1941-1949.
10. Athanasiadou A, Stavroyianni N, Saloum R, Asteriou O, Anagnostopoulos A, Fassas A. Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases [letter]. Leukemia. 2004;18:1029-1031.
11. Deininger MWN. Cytogenetic studies in patients on imatinib. Semin Hematol. 2003;40:50-55.
12. Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma. 2004;45:2197-2203.
13. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia. 2004;18:1340-1346.
14. Gozzetti A, Tozzuoli D, Crupi R, et al. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI) [letter]. Eur J Haematol. 2003;71:313-314.
15. McMullin MF, Humphreys M, Bryne J Russell NH, Cuthbert RJ, O'Dwyer ME. Chromosomal abnormalities in Ph-cells of patients on imatinib [letter]. Blood. 2003;102:2700-2701.
16. Abruzzese E, Cantonetti M, Morino L, et al. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports [letter]. J Clin Oncol. 2003;21:4256-4258.
17. Au WY, Ma SK, Kwong YL. The occurrence of Philadelphia chromosome (Ph) negative leukemia after hematopoietic stem cell transplantation for Ph positive chronic myeloid leukemia: implications for disease monitoring and treatment. Leuk Lymphoma. 2003;44:1121-1129.
18. Cherrier-De Wilde S, Rack K, Vannuffel P, Delannoy A, Hagemeijer A. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission [letter]. Leukemia. 2003;17:2046-2048.
19. Mauro MJ, Loriaux M, Deininger MW. Ph-positive and Ph-negative myeloproliferative syndromes may co-exist [letter]. Leukemia. 2004;18:1305-1307.
20. Raskind WH, Ferraris AM, Najfeld V, Jacobson RJ, Moohr JW, Fialkow PJ. Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukaemia. Leukemia. 1993;7:1163-1167.
21. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pre-transplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999;94:1814-1819.
22. Chee YL, Vickers MA, Stevenson D, Holyoake TL, Culligan DJ. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterized by the emergence of complex Philadelphia-negative clones. Leukemia. 2003;17:634-635.
23. Bacher U, Hochhaus A, Berger U, et al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia. 2005;19:460-463.
24. Kowitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukaemia developing after imatinib mesylate therapy for chronic myeloid leukaemia. Blood. 2006;108:2811-2813.
25. Juvonen E, Aimolhati A, Volin L, Ruutu T. The prognostic value of in vitro cultures of erythroid and megakaryocyte progenitors in myelodysplastic syndromes. Leuk Res. 1999;23:889-894.
26. Marisavljevic D, Rolovic Z, Sefer D, et al. Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes. Med Oncol. 2002;19:249-259.
27. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal progenitor in vitro. Blood. 2004;103:523-529.
28. Sawada K Growth characteristics of myelodysplastic CD34+ cells. Leuk Lymphoma. 1998;29:49-60.
29. Panteli K, Zagorianakou N, Bai M, Katsaraki A, Agnantis NJ, Bourantas K. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. Eur J Haematol. 2004;72:410-415.
30. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81:1398-1401.
31. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Cancer. 2003;98:1905-1911.
32. Lyn Y, Bruyere H, Horsman DE, et al. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet. 2006;170:16-23.